OKUR: OnKure Therapeutics Inc Price/Earnings to Growth Multiple

Symbol and logo of brand OnKure Therapeutics Inc (OKUR)

The valuation-to-earnings ratio demonstrates the asset's market volatility, with the 0.00 value reflecting the most recent figure. OnKure Therapeutics Inc (OKUR) develops selective HDAC inhibitors to reduce therapy toxicity. Proprietary molecules ensure long-term monopoly status and high margins. The company is currently expanding its portfolio of precision drugs for solid tumors following the completion of a reverse merger.

Price/Earnings to Growth Ratio: OnKure Therapeutics, Inc. (OKUR) for 10/08/2024 - 11/17/2026

Metric breakdowns and analytics for OnKure Therapeutics Inc (OKUR)

Fundamental company analysis:OnKure Therapeutics Inc (OKUR)
Mass-produced product of OnKure

When screening issuers for financial reliability, investors utilize this indicator to identify undervalued assets. The metric compares the P/E ratio with earnings growth rates, where a value below one signals potential price appreciation. For OnKure Therapeutics Inc (OKUR), such calculations account for the efficiency of implementing green protocols and laboratory optimization. By analyzing the PEG momentum indicator, one can determine the balance between share price and biotech expansion. This chart's price action helps avoid false breakouts.

Competitors of OnKure Therapeutics Inc

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Aura Biosciences Inc - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics CADL|accuray.com - PEG Multiple|SLS: Price/Earnings to Growth Ratio|ACTU (actuatetherapeutics.com) - Price/Earnings to Growth Multiple|CTOR - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio tuhurabio.com|PEG Multiple Protara Tx|Price/Earnings to Growth Multiple FATE (Fate Therapeutics Corp)|Price/Earnings to Growth Ratio WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|Champions Oncology (CSBR) - Price to Earnings Adjusted for Growth Rate|XBiotech - PEG Multiple|CEL-SCI (CVM) - Price/Earnings to Growth Multiple|OS Therapies Inc (OSTX) - Price/Earnings to Growth Ratio|radiopharmtheranostics.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Artiva Biotherapeutics Inc.|Price to Earnings Adjusted for Growth Rate Adlai Nortye Ltd. ANL|PEG Multiple VERU|TPST - Price to Earnings Adjusted for Growth Rate|PEG Multiple XLO (Xilio Therapeutics)|RENB - Price/Earnings to Growth Multiple|muraloncology.com - PEG Multiple|KAPA - PEG Multiple|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple